ADMETRx and CeeTox Formalize Collaborative Relationship to Benefit Clients.

KALAMAZOO, Mich. -- ADMETRx, a CRO (contract research organization) committed to providing the best in vitro ADME discovery support possible, is pleased to announce a strategic partnership with CeeTox, a CRO committed to the same high standards of performance using in vitro models to predict toxicity. The logical integration of toxicity screening and ADME testing in drug discovery lead selection and optimization, particularly in the assessment of potential drug-drug interactions and idiosyncratic toxicities, means the ADMETRx-CeeTox alliance will provide the pharmaceutical and biotech industry with maximum efficiencies to improve effectiveness in discovery decision-making.

ADMETRx President Jay Goodwin, PhD, says, "ADMETRx and CeeTox have a long-standing collaborative relationship including having worked together in big pharma. We both recognize how complementary data integration can offer significant advantages to our clients in selecting candidates for advancement." CeeTox Founder and CSO, Jim McKim, PhD DABT, concurs and goes on to say, "By aligning with ADMETRx, we improve the efficiency of early discovery research even further by providing comprehensive data. This results in reduced development time and a higher probability of success in preclinical animal testing, and ultimately brings safer drugs to market."

ADMETRx provides high-value solutions to address the drug discovery needs of its clients. Its high-quality data generation and integration via advanced techniques and technologies leads to cost savings and improved drug discovery effectiveness. CeeTox offers unique and robust in vitro toxicity screening via a proprietary algorithm that incorporates multiple endpoint analyses and dose-response profiles to determine the "Ctox" value, a prediction of toxicity in vivo.

Both companies are solutions-oriented, preclinical research CROs and operate state-of-the-art laboratories in the Southwest Michigan life-sciences hub. Each company is committed to assisting clients achieve their drug discovery goals in the face of industry-wide budget constraints and market pressures to speed development. The synergies created by the ADMETRx-CeeTox alliance include the advantage of efficiencies in location and communication, which will help clients meet the industry challenge to improve the effectiveness of drug discovery -- advancing better candidates with greater frequency.

For information on ADMETRx, please visit www.admetrx.com or contact Marie Warren, Client Relations Manager, by calling [phone] or email to [e-mail].

For information on CeeTox please visit www.ceetox.com or contact Lorraine Alden, Sales and Marketing Coordinator, by calling [phone] or email to [e-mail].